Effects of supratherapeutic doses of aleglitazar on QT prolongation.
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2011
At a glance
- Drugs Aleglitazar; Moxifloxacin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 27 Dec 2011 New trial record
- 21 Nov 2011 Results published in the Journal of Cardiovascular Pharmacology.